News
XNCR
25.04
+1.66%
0.41
Weekly Report: what happened at XNCR last week (1005-1009)?
Weekly Report · 1d ago
Xencor: Better Funding For Obexelimab
Seeking Alpha · 5d ago
Weekly Report: what happened at XNCR last week (0928-1002)?
Weekly Report · 10/05 09:04
William Blair refreshes its analyst conviction list
Seeking Alpha · 10/01 16:01
Wells Fargo Reaffirms Their Buy Rating on Xencor (XNCR)
TipRanks · 09/29 22:15
Xencor Price Target Raised to $29.00/Share From $27.00 by Truist Securities
Dow Jones · 09/28 15:28
Truist Securities Reiterates Buy on Xencor, Raises Price Target to $29
Benzinga · 09/28 15:17
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and IQVIA Holdings (IQV)
TipRanks · 09/28 11:32
Weekly Report: what happened at XNCR last week (0921-0925)?
Weekly Report · 09/28 09:04
Analysts Are Bullish on Top Healthcare Stocks: Staar Surgical (STAA), Xencor (XNCR)
TipRanks · 09/25 13:50
Xencor Is Maintained at Neutral by B of A Securities
Dow Jones · 09/21 17:52
Xencor Price Target Raised to $26.00/Share From $20.00 by B of A Securities
Dow Jones · 09/21 17:52
B of A Securities Maintains Neutral on Xencor, Raises Price Target to $26
Benzinga · 09/21 17:42
Weekly Report: what happened at XNCR last week (0914-0918)?
Weekly Report · 09/21 09:04
Weekly Report: what happened at XNCR last week (0907-0911)?
Weekly Report · 09/14 09:04
Xencor Is Maintained at Overweight by Barclays
Dow Jones · 09/11 14:05
Barclays Maintains Overweight on Xencor, Raises Price Target to $35
Benzinga · 09/11 13:56
Xencor price target raised to $35 from $27 at Barclays
TipRanks · 09/11 09:35
Xencor (XNCR) Receives a Buy from Barclays
TipRanks · 09/11 09:16
Weekly Report: what happened at XNCR last week (0831-0904)?
Weekly Report · 09/07 09:04
More
Webull provides a variety of real-time XNCR stock news. You can receive the latest news about Xencor through multiple platforms. This information may help you make smarter investment decisions.
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.